Successful Integration of Nonclinical and Clinical Findings in Interpreting the Clinical Relevance of Rodent Neoplasia with a New Chemical Entity

Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin

(2014) Rao N.V.S. Mamidi et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin

(2014) Sandra De Jonghe et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

(2014) J.-F. Yale et al.   DIABETES OBESITY & METABOLISM

Nonclinical Toxicology Assessments Support the Chronic Safety of Dapagliflozin, a First-in-Class Sodium-Glucose Cotransporter 2 Inhibitor

(2013) Mark Tirmenstein et al.   INTERNATIONAL JOURNAL OF TOXICOLOGY

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor

(2012) Paul Nyirjesy et al.   CURRENT MEDICAL RESEARCH AND OPINION

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Occurrence of Spontaneous Amphophilic-Vacuolar Renal Tubule Tumors in Sprague-Dawley Rats from Subchronic Toxicity Studies

(2012) Torrie A. Crabbs et al.   TOXICOLOGIC PATHOLOGY

Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

(2011) V. Gorboulev et al.   DIABETES

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Renal glucose reabsorption inhibitors to treat diabetes

(2011) Clifford J. Bailey   TRENDS IN PHARMACOLOGICAL SCIENCES

Discovery of Canagliflozin, a NovelC-Glucoside with Thiophene Ring, as Sodium-Dependent Glucose Cotransporter 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus(1)

(2010) Sumihiro Nomura et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of NovelN-β-d-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes

(2010) Chun-Hsu Yao et al.   JOURNAL OF MEDICINAL CHEMISTRY

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Chemical Carcinogenesis

(2010) S. M. Cohen et al.   TOXICOLOGICAL SCIENCES

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice

(2009) Ryuichi Moriya et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target

(2009) R. Santer et al.   Clinical Journal of the American Society of Nephrology

Chemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment

(2009) Helmut Greim et al.   CRITICAL REVIEWS IN TOXICOLOGY

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE

Slc2a5 (Glut5) Is Essential for the Absorption of Fructose in the Intestine and Generation of Fructose-induced Hypertension

(2008) Sharon Barone et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Spontaneous Occurrence of a Distinctive Renal Tubule Tumor Phenotype in Rat Carcinogenicity Studies Conducted by the National Toxicology Program

(2008) Gordon C. Hard et al.   TOXICOLOGIC PATHOLOGY